Mona Kafka, Giulia Giannini, Nastasiia Artamonova, Hannes Neuwirt, Heidemarie Ofner, Gero Kramer, Thomas Bauernhofer, Ferdinand Luger, Thomas Höfner, Wolfgang Loidl, Hubert Griessner, Lukas Lusuardi, Antonia Bergmaier, Andreas Berger, Thomas Winder, Sarah Weiss, Severin Bauinger, Steffen Krause, Martin Drerup, Elmar Heinrich, Magdalena Schneider, Stephan Madersbacher, Sonia Vallet, Franz Stoiber, Sarah Laimer, Stephan Hruby, Gert Schachtner, Udo Nagele, Sebastian Lenart, Anton Ponholzer, Jacob Pfuner, Clemens Wiesinger, Christoph Kamhuber, Ecan Müldür, Jasmin Bektic, Wolfgang Horninger, Isabel Heidegger
INTRODUCTION: Two randomized trials demonstrated a survival benefit of triplet therapy (androgen deprivation therapy [ADT]) plus androgen receptor pathway inhibitor [ARPI] plus docetaxel) over doublet therapy (ADT plus docetaxel), thus changing treatment strategies in metastatic hormonesensitive prostate cancer (mHSPC). PATIENTS AND METHODS: We conducted the first real-world analysis comprising 97 mHSPC patients from 16 Austrian medical centers, among them 79.4% of patients received abiraterone and 17...
January 4, 2024: Clinical Genitourinary Cancer